Co-development & investment opportunity: first-in-class P2Y2 therapeutics for obesity

Methodology: ePurines is advancing a drug discovery program focused on selective P2Y2 receptor antagonists for obesity, metabolic syndrome, and cardiometabolic diseases. The approach combines structure-guided medicinal chemistry, in vitro receptor pharmacology, functional cell-based assays, biomarker profiling, and in vivo efficacy studies in relevant metabolic disease models. Computational methods, including AI-assisted analysis of multidimensional biological and clinical datasets, may be used to identify biomarkers, stratify cardiometabolic risk, and support translational decision-making.

Metrics: Key performance indicators include potency and selectivity at the P2Y2 receptor (target low-nanomolar range), favorable ADME/PK characteristics, reduction in body weight gain, improvement in insulin sensitivity and glucose tolerance, attenuation of inflammation, and favorable effects on renal and cardiovascular biomarkers in preclinical models. Success metrics also include identification of development candidates suitable for IND-enabling studies.

Datasets: Data sources may include internally generated pharmacology and efficacy datasets, published omics and cardiometabolic datasets, and collaborative clinical datasets to evaluate biomarkers associated with obesity, insulin resistance, chronic kidney disease, and cardiometabolic risk.

Validation Plan: Candidate molecules will undergo iterative optimization and validation through receptor binding studies, cellular functional assays, dose-response studies, and testing in established animal models of obesity and metabolic dysfunction. Independent academic and industry collaborations will be pursued to strengthen translational validation.

Next Steps: We seek strategic partners and investors to accelerate lead optimization, preclinical development, biomarker validation, and preparation for IND-enabling studies, with opportunities for co-development, licensing, and commercialization.